San Jose, California (PRWEB) March 25, 2014

Follow us on LinkedIn High prevalence of cancer worldwide and growing number of related casualties is creating an immediate need for effective diagnosis and therapy. Despite continuous research and the development of novel drugs, cancer remains unbeatable in most cases. The discovery of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) and their molecular mechanism is forecast to play an indispensable role in the future of cancer diagnostics and treatment. CTCs are cells dispersed from the primary tumor and found in peripheral blood circulation. The detection of CTCs and their numbers present important clues on the presence of cancer and the extent of its spread within the body. Clinical applications of CTC diagnostics are currently limited with high cost being the primary limiting factor. Unmet medical needs in the field of effective screening is however expected result in continuous flow of R&D investments in CTCs and CSCs. CTC based diagnostics involve a simple blood test and is increasingly being preferred over painful bone marrow aspirations and surgical biopsies to diagnose and analyze cancer metastasis.

CTC quantification and analyses based on molecular research also provides the potential to develop personalized cancer treatment regimens, which is garnering interest among scientific communities. Better, faster, and more user-friendly methods to detect and characterize CTCs will witness increased demand in the coming years. PCR-based (nucleic acid-based) identification methods are the most effective and sensitive for CTC genetic profiling, scoring over immunocytometric (protein-based) methods for molecular characterization of CTCs. RT-PCR and qPCR are highly specific techniques that are widely used to identify and amplify CTCs. CellSearch is the only FDA-approved automated system that offer combined enrichment, staining, and scanning of CTCs.

Cancer Stem Cells (CSCs) are the bulk cells within a tumor carrying its proliferative capability. CSCs remain unaffected by cancer treatment strategies, including chemotherapy and cause tumor relapse or re-occurrence thereby creating the need for new therapeutic drugs that destroy CSCs. The technology is still under extensive research. Biotechnology and pharmaceutical companies are increasingly shifting focus to anti-cancer therapeutics that target cancer stem cells and their regenerative mechanisms.

As stated by the new market research report on Circulating Tumor Cells and Cancer Stem Cells Technologies, the United States and Europe are the largest markets worldwide. The United States remains the undisputed leader in CTC diagnostics. Asia-Pacific is forecast to emerge as the fastest growing market driven by developing healthcare infrastructure, growing patient awareness, increasing per capita healthcare spends, focus on quality healthcare services, and the urgent need for advanced cancer diagnostics.

Key players covered in the report for CTC diagnostics include Adnagen GmbH, ApoCell Inc., Biocep LTD, Biocept Inc., Biofluidica Microtechnologies LLC, Celltrafix Inc., Clearbridge Biomedics, Creatv Microtech Inc., Cynvenio Biosystems Inc., Ikonisys Inc., IVDiagnostics Inc., Janssen Diagnostics LLC, Epic Biosciences Inc., Rarecells SAS, Screencell, Stemcell Technologies Inc. Market participants in CSC research include Alchemia Limited, Amgen Inc., Exelixis Inc., Formula Pharmaceuticals, GlaxoSmithKline Plc, Geron Corp, Infinity Pharmaceuticals, Kalobios Pharmaceuticals Inc., Novartis AG, OncoMed Pharmaceuticals Inc., Roche Diagnostics, and Verastem Inc., among others.

The research report titled Circulating Tumor Cells and Cancer Stem Cells Technologies: A Global Strategic Business Report announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, drivers, key issues and challenges. The study also provides insights into CTC biology and CTC detection technologies, including CellSearch, ISET, CTC Chip, FAST, FISH, etc. The report provides market estimates and projections for CTC Diagnostics for all major geographic markets including the United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific, and Rest of World. Exclusive coverage is presented on Cancer Stem Cells biology, Surface Markers, Signaling Pathways, and Pipeline drugs.

For more details about this comprehensive market research report, please visit http://www.strategyr.com/Circulating_Tumor_Cells_CTCs_and_Cancer_Stem_Cells_CSCs_Technologies_Market_Report.asp

About Global Industry Analysts, Inc. Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc. Telephone: 408-528-9966 Fax: 408-528-9977 Email: press(at)StrategyR(dot)com Web Site: http://www.StrategyR.com/

View original post here:
Need for Advanced Cancer Diagnostics Drives Demand for Circulating Tumor Cells & Cancer Stem Cells Technologies ...